0.022
전일 마감가:
$0.022
열려 있는:
$0.022
하루 거래량:
22,663
Relative Volume:
6.62
시가총액:
$N/A
수익:
$9.94M
순이익/손실:
$-144.49M
주가수익비율:
-0.00436
EPS:
-5.05
순현금흐름:
$-103.90M
1주 성능:
+0.00%
1개월 성능:
-79.82%
6개월 성능:
-98.42%
1년 성능:
-99.50%
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
SYRS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SYRS
Syros Pharmaceuticals Inc
|
0.022 | 0 | 9.94M | -144.49M | -103.90M | -5.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.91 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
510.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
313.33 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
541.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.79 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2020-11-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-09-22 | 개시 | Alliance Global Partners | Buy |
2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-03-08 | 재개 | JMP Securities | Mkt Outperform |
2019-02-14 | 재개 | Oppenheimer | Outperform |
2018-11-05 | 업그레이드 | ROTH Capital | Neutral → Buy |
2018-03-13 | 재확인 | Wedbush | Outperform |
2017-10-31 | 재개 | Piper Jaffray | Overweight |
2017-10-23 | 개시 | ROTH Capital | Neutral |
2017-08-10 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
모두보기
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities LawsSYRS - ACCESS Newswire
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN
Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World
Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com
Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com
Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch
Syros to delist from Nasdaq, deregister from SEC - MSN
Syros Pharmaceuticals Inc (SYRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):